164 related articles for article (PubMed ID: 37656950)
1. Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
Liu J; Amini A; Govindarajan A; Abuali T; Mambetsariev I; Massarelli E; Villaflor V; Villalona-Calero M; West H; Williams T; Salgia R
JCO Precis Oncol; 2023 Sep; 7():e2200445. PubMed ID: 37656950
[TBL] [Abstract][Full Text] [Related]
2. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
4. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
6. Early-stage anaplastic lymphoma kinase (
Chen MF; Chaft JE
Transl Lung Cancer Res; 2023 Feb; 12(2):337-345. PubMed ID: 36895922
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris MG; Mitsudomi T; Peters S
Transl Lung Cancer Res; 2023 Apr; 12(4):824-836. PubMed ID: 37197636
[TBL] [Abstract][Full Text] [Related]
8. Perioperative targeted therapy for oncogene-driven NSCLC.
Liu SY; Zhang JT; Zeng KH; Wu YL
Lung Cancer; 2022 Oct; 172():160-169. PubMed ID: 35644704
[TBL] [Abstract][Full Text] [Related]
9. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
[TBL] [Abstract][Full Text] [Related]
10. Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review.
Ortega-Franco A; Calvo V; Franco F; Provencio M; Califano R
Transl Lung Cancer Res; 2020 Dec; 9(6):2656-2673. PubMed ID: 33489825
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
Lee JM; McNamee CJ; Toloza E; Negrao MV; Lin J; Shum E; Cummings AL; Kris MG; Sepesi B; Bara I; Kurtsikidze N; Schulze K; Ngiam C; Chaft JE
J Thorac Oncol; 2023 Nov; 18(11):1458-1477. PubMed ID: 37451404
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
[TBL] [Abstract][Full Text] [Related]
14. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
16. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review.
Chen J; Xu C; Lv J; Lu W; Zhang Y; Wang D; Song Y
Transl Lung Cancer Res; 2023 Apr; 12(4):895-908. PubMed ID: 37197619
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
19. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
20. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
